Clinical Trial Update: A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) [Phase 4]

View source ↗

Summary

Phase 4 study completed evaluating efficacy and tolerability of Caelyx in patients with epithelial ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer

Drugs mentioned

• Caelyx (liposomal doxorubicin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Ovarian Neoplasms | Phase 4 | Status: COMPLETED | Results posted: 2009-07-16